Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    Gefitinib - Iressa

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,912Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    28/03/2025 Ajinomoto Company
    Japan
    		 AstraZeneca Korea Ltd. Su3042-9-ND Gefitinib 2014-10-31 Ajinomoto Omnichem Belgium Cooppallaan 91, Wetteren, Oost-Vlaanderen, B-9230, Belgium
    28/03/2025 AstraZeneca
    United Kingdom
    		 AstraZeneca Korea Ltd. 661-1-ND Gefitinib 2003-05-27 AstraZeneca UK Ltd. United Kingdom Silk Road Business Park, Macclesfield, Cheshire SK 10 2NA, UK